ADH6

Across TCGA pan-cancer cohorts, ADH6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADH6 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ADH6 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ADH6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, CHOL, and SKCM are the cancer types where ADH6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.652	.016	24	view →
CHOL	DFS	Median	All	0.100	0.496	.006	21	view →
SKCM	DFS	Median	III,IV	0.149	0.660	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ADH6–UCEC (OS)

Open the UCEC breakdown →